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Deep brain stimulation has been successfully used in the 
treatment of Parkinson’s disease for more than two decades, with 
deep brain stimulation of the subthalamic nucleus significantly 
improving motor function. Symptoms of the disease (e.g., tremor, 
rigidity, bradykinesia) are measured by the Unified Parkinson’s 
Disease Rating Scale Part III, but uncertainty remains concerning 
the areas in and around the subthalamic nucleus that are associated 
with each particular symptoms included in UPDRS-III. Here, we 
retrospectively examine a cohort of Parkinson’s patients implanted 
at the Center for Neuromodulation in the Ohio State Wexner 
Medical Center. By combining anatomically-detailed pre-operative 
magnetic resonance imaging with post-operative computed 
tomographic imaging, we accurately determine the actual location 
of implanted electrode leads, then model a volume of tissue 
activation around each electrode to estimate the neuronal cell 
bodies and fiber tracts that are most likely to be affected by the 
stimulation parameters (i.e., voltage, pulse width, and frequency) 
that are programmed by clinicians during follow-up. By correlating 
these volumes of tissue activation with each motor function 
subscore, we have built three-dimensional statistical and 
probabilistic maps in and around the subthalamic nucleus that will 
allow clinicians to target lead placement and stimulation to 
particular deep brain regions based on patient-specific symptoms. 
 
 
 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  6	  
 
 
 
 
 
 
 
 
 
 
 
 
PARKINSON’S DISEASE 
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OVERVIEW 
 
 Approximately 60,000 new Parkinson’s disease (PD) diagnoses are made 
each year in the United States, and disease prevalence for those over 65 years of 
age is estimated to be 950 per 100,000 (Hirtz et al., 2007). First described by James 
Parkinson in 1817 in his “Essay on the Shaking Palsy,” between 4–6 million 
people worldwide suffer from the disease (parkinson.org), making it the second 
most common neurodegenerative disease after Alzheimer’s (Wirdefeldt et al., 
2011). Cardinal symptoms of the idiopathic disease include motor, autonomic, 
psychiatric, and cognitive dysfunction, all of which play a role in severely 
debilitating the lives of those afflicted. 
 
 
SYMPTOMS 
 
Motor 
Diagnostic criteria (at least 2 of 3): 
v resting tremor in appendicular and/or orofacial muscles at 4–6 Hz 
v bradykinesia 
v rigidity of arms, legs, trunk 
Other: 
w akinesia 
w postural reflex impairment, leading to instability and retropulsion 
w stooped posture  
w shuffling gait  
w freezing gait 
w masked facial expression (i.e., hypomimia) 
 w hypophonia 
w micrographia  
 
Autonomic 
w paresthesias (e.g., ‘pins and needles’, tingling, burning) 
w seborrheic dermatitis, leading to dandruff 
w hypotension, including orthostatic hypotension 
w constipation  
w erectile dysfunction in men  
w early satiety when eating 
w decreased reflexive blinking and swallowing 
w hyperhidrosis 
w urinary urgency, frequency, and incontinence 
w sialorrhea due to slowed swallowing 
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Psychiatric 
w depression, including anhedonia 
w anxiety 
w irritability 
w psychosis, including hallucinations 
 
Cognitive 
w attention deficits 
w memory impairment 
w visuospatial impairment 
w endorsement of slowed processing 
w dementia 
 
Symptoms preceding motor dysfunction 
w anosmia 
w sleep disturbances, including REM behavior disorder 
 
 
ETIOLOGY 
 
 Epidemiological studies have indicated a role for both genetic and 
environmental factors in pathogenesis of the disease. Distinct genes appear to be 
involved in familial versus sporadic disease, and diet/lifestyle choices, as well as 
occupational exposures, may positively or negatively impact an individual’s risk 
of developing PD (Wirdefeldt et al., 2011). While the biomolecular mechanisms 
that lead to striatal neurodegeneration are being elucidated by virtue of such 
epidemiological findings, the ostensibly complex etiology of PD eludes rigorous 
description in the literature. 
 Theories exist concerning PD origins in defective protein handling, 
mitochondrial dysfunction, oxidative stress, and inflammation (Wirdefeldt et al., 
2011), but clinical treatment of the disease has yet to see dramatic improvements 
as a result of these insights. Neither adequate diagnostic biomarkers nor 
sophisticated pharmacological interventions currently exist for PD. 
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MOTOR EXAMINATION 
 
UNIFIED PARKINSON’S DISEASE RATING SCALE - PART III 
(Fahn et al., 1987) 
 
18. Speech  
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked Impairment, difficult to understand. 
4 = Unintelligible.  
 
19. Facial Expression  
0= Normal. 
1 = Minimal hypomimia, could be normal “Poker Face.” 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed face with severe or complete loss of facial    
expression; lips parted ¼ inch or more. 
 
20. Tremor at Rest (Face, lips, chin, head, upper and lower extremities.) 
0 = Absent.  
1 = Slight and infrequently present.  
2 = Mild in amplitude and persistent. Or moderate in amplitude, but 
only intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
 
21. Action or Postural Tremor of Hands  
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well  
as action. 
4 = Marked in amplitude; interferes with feeding.  
 
22. Rigidity (Neck, upper and lower extremities. Judged on passive 
movement of major joints with patient relaxed in sitting position. 
Cogwheeling to be ignored.)  
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0 = Absent. 
1 = Slight or detectable only when activated by mirror or other 
movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty.  
 
23. Finger Taps (Patient taps thumb with index finger in rapid succession.) 
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2= Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task.  
 
24. Hand Movements (Patient opens and closes hands (Pronation-
supination movements of hands, vertically and horizontally, with as large 
an amplitude as possible, both hands simultaneously.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2= Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task.  
 
25. Rapid Alternating Movements of Hands (Pronation-supination 
movements of hands, vertically and horizontally, with as large an 
amplitude as possible, both hands simultaneously.)  
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task.  
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26. Leg Agility (Patient taps heel on the ground in rapid succession 
picking up entire leg. Amplitude should be at least 3 inches.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2= Moderately impaired. Definite and early fatiguing. May have 
occasional arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or 
arrests in ongoing movement. 
4 = Can barely perform the task.  
 
27. Arising from Chair (Patient attempts to rise from a straightbacked 
chair, with arms folded across chest.)  
0 = Normal. 
1 = Slow; or may need more than one attempt.  
2 = Pushes self up from arms of seat.  
3 = Tends to fall back and may have to try more than one time, but can 
get up without help.  
4 = Unable to arise without help.  
 
28. Posture  
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older 
person.  
2 = Moderately stooped posture, definitely abnormal; can be slightly 
leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning 
to one side. 
4 = Marked flexion with extreme abnormality of posture.  
 
29. Gait  
0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination 
(hastening steps) or propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have 
some festination, short steps, or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance.  
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30. Postural Stability (Response to sudden, strong posterior displacement 
produced by pull on shoulders while patient erect with eyes open and feet 
slightly apart. Patient is prepared.)  
0 = Normal.  
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner.  
3 = Very unstable, tends to lose balance spontaneously.  
4 = Unable to stand without assistance.  
 
31. Body Bradykinesia and Hypokinesia (Combining slowness, hesitancy, 
decreased arm swing, small amplitude, and poverty of movement in 
general.)  
0 = None.  
1 = Minimal slowness, giving movement a deliberate character; could 
be normal for some persons. Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is 
definitely abnormal. Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
 
 
TREATMENT 
 
The symptomatic treatment of Parkinson's disease (PD) is primarily 
pharmacological in nature and is prescribed to minimize motor and non-motor 
symptoms. Medical treatment options include various dopaminergic options, 
such as the dopamine precursor, levodopa, with or without agents to increase 
peripheral availability of the precursor via decarboxylase or catechol-O-methyl 
transferase inhibition; dopamine agonists such as pramipexole, ropinirole, and 
rotigotine; and monoamine oxidase B inhibitor such as rasagiline and selegiline. 
These may be combined with non-dopaminergic medications, such as 
benztropine mesylate and trihexyphenidyl, both of which have anticholinergic 
activity. 
In many cases, pharmacological therapy is unable to provide satisfactory 
symptom control as the disease progresses and patients may develop disabling 
side effects after long-term use of PD medications (Stocchi et al., 2008). As 
neurodegeneration progresses, medications may provide shorter and shorter 
periods of symptom relief, requiring larger and larger doses that precipitate 
debilitating dyskinesias. When this stage of PD is reached, surgical treatment 
may be indicated to provide relief of symptoms and allow for simplification 
and/or reduction of medication therapies.  
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HISTORY 
 
Descriptions of surgical treatment for PD date back to the first half of the 
20th century, and focus primarily on ablative procedures. This approach abated 
somewhat with the introduction of dopaminergic pharmacological interventions, 
such as levodopa, but made a resurgence in the 1990s (Bronstein et al., 2011). By 
the beginning of the 21st century, however, ablative lesioning was by and large 
abandoned for the functional lesioning made possible by electrical stimulation, 
which has the crucial advantage of being revisable and adjustable. The new 
technique, known as deep brain stimulation (DBS), was applied to novel 
subcortical structures, and the STN became one of the most commonly targeted 
deep nuclei in the treatment for PD (Bergman et al., 1990; DeLong 1990; Aziz et 
al., 1991). Since the U.S. Food and Drug Administration approved DBS for the 
treatment of PD in 2002, more than 100,000 implants have been placed 
throughout the world, according to Medtronic Inc., a leading manufacturer of 
DBS technologies. 
 
 
PROCEDURE 
 
 Although proven safe and effective, DBS therapy is most effective when 
applied to the correctly selected PD patient (Bronstein et al., 2011), and nearly 
one-third of DBS failures are attributed to improper patient selection (Okun et 
al., 2005). In the most expert neurological centers, multidisciplinary teams of 
neurologists, neurosurgeons, neuropsychologists, and even psychiatrists 
evaluate a patient’s candidacy for surgery, determining their individual risk-
benefit analysis. It is worth noting, however, that there is evidence that DBS 
interventions (for patients with non-atypical parkinsonism) may have a greater 
positive impact on quality of life measures when delivered in earlier stages of 
Parkinson’s disease progression (Schüpbach et al., 2007; Merola et al., 2015). 
 After pre-screening, baseline assessments are scheduled where, among 
other measures, UPDRS-III scores are collected after an approximately 12 hour 
washout of PD medications, then after a PD medication dose at maximum 
pharmacological efficacy, which is typically achieved 45–90 minutes after oral 
ingestion. Experts agree that a 30% improvement in UPDRS-III score with 
dopaminergic medications is the single-best predictor of a patient’s response to 
DBS (Charles et al., 2002; Kleiner-Fisman et al., 2006). 
 If cleared for the procedure, the day of surgery involves standard surgical 
preparation in addition to stereotactic head-frame placement in institutions that 
use frame-based navigation systems. After the frame is attached to the patient’s 
skull, neuroimaging data is gathered (via MRI, CT, ventriculography, or some 
combination of these technologies), then fed into specialized, interactive 
neurosurgical planning software which allows the surgical team to find 
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implantation trajectories that reach the subcortical target while avoiding major 
blood vessels and the sulci of the cortex. 
 With multiple trajectories in mind, the surgeon creates a burr hole that 
provides access for the slow insertion of a microelectrode down to target. During 
this process, electrophysiologists monitor the electrical activity recorded by the 
microelectrode to verify correct placement. The basal ganglia nuclei in the 
immediate vicinity of the STN display consistent baseline firing patterns, as well 
as predictable responses to active and passive movement of the patient’s 
appendicular and orofacial muscles. For this reason, many functional 
neurosurgeons prefer to perform at least part of their DBS procedures on awake 
and alert patients. 
 To aide in targeting, supratherapeutic doses of electrical stimulation are 
applied to identify areas associated with side effects (e.g., paresthesias, 
involuntary muscle contractions, autonomic responses), which must be avoided, 
and areas associated with reduction in PD motor symptoms. Once the surgical 
team reaches a consensus vis-à-vis the optimal location for stimulation, the 
microelectrode is removed and replaced with the DBS lead. 
 Following a final round of electrophysiological verification with the final 
implant, the entire procedure may be repeated on the contralateral brain 
hemisphere, if appropriate and determined in advance, and intraoperative 
neuroimaging, by way of MRI or CT, is completed. If DBS lead locations are 
acceptable to the neurosurgeon and evaluation of hemorrhage or 
pneumocephalus is normal, the skull and skin incisions are closed, the 
stereotactic frame is removed, and the patient is sent to recovery. Depending on 
the patient’s condition, implantation of the internal pulse generator into the 
infraclavicular space of the external chest wall or the abdomen, with subsequent 
subcutaneously-tunneled, wired connections to the DBS lead, may be performed 
during the same hospitalization or completed within days or weeks. For elderly 
patients or those with certain conditions (e.g., cognitive impairment), 
contralateral implantation of a second DBS lead and internal pulse generator 
may be scheduled within one month. It should be noted, however, that adequate 
relief of PD symptoms is often achieved with unilateral neurostimulation. 
 Incidence of surgical complications varies by source and may include 
intracranial hemorrhage (0–10%), stroke (0–2%), infection (0–15%), lead erosion 
without infection (1–2.5%), lead fracture (0–15%), lead migration (0–19%), and 
death (0–4.4%) (Weaver et al., 2009; Blomstedt & Hariz, 2005; Videnovic & 
Metman, 2008; Hamani & Lozano, 2006; Deuschl et al., 2006), although advances 
in technology and technique are continuously reducing these figures (Bronstein 
et al., 2011). 
 
 
TITRATION 
 
 Postoperative care focuses on the titration of stimulation parameters to 
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achieve maximal efficacy. Typical parameters for STN-DBS in PD involving a 
monopolar configuration include voltages between 2.5–3.5 V, pulse widths of 60–
90 µs, and frequencies of 130–180 Hz. These may be exceeded if doing so lessens 
the severity of symptoms without causing side effects, which include sensory 
and motor changes such as involuntary contraction of face, arm, and leg muscles, 
dysarthritic speech, dystonic posturing, spontaneous eye deviation, as well as 
changes in heart rate, blood pressure, and respiratory rate. It is also critical not to 
exceed a total charge density of 30 µcoulomb/cm2, since the application of 
electrical stimulation above this threshold may lead to tissue damage. 
 Because each DBS lead is equipped with 4 electrode contacts, the clinician 
(i.e., neurologist, neurosurgeon, nurse, or physician assistant) may test the 
efficacy of a given monopolar configuration with the internal pulse generator 
serving as anode and any of the four contacts serving as cathode. In some cases, 
bipolar configurations, wherein the anode is the internal pulse generator and the 
cathode comprises 2 electrode contacts, produce the best results; in others, 
interleaving stimulation, involving alternating pulses from 2 unique 
configurations, is optimal (Moreau et al., 2008). With the help of intraoperative 
neurophysiological data and postoperative imaging, the clinician systematically 
evaluates the adverse and beneficial effects of a wide range of possible 
configurations and stimulation parameters, and typically achieves optimum 
settings within 4–5 titration sessions over 3–6 months (Bronstein et al., 2011). 
Once set, the neurostimulator is typically active at these parameters 24 hr/day, 
with some patients receiving instructions for slight adjustments in stimulation at 
home as needed. 
 Side effects of DBS for movement disorders include: suicidal ideation, 
depression, gastrointestinal disturbances, nausea, muscle weakness or partial 
paralysis, jolting or shocking sensation, numbness, paresthesias, facial flushing 
and motor contraction, dizziness, headaches pain, changes in vital signs, 
hyperactivity or euphoria, pain or discomfort, dry mouth, itching at the surgical 
site, insomnia, increased fatigue, cognitive disturbance,  restlessness, weight gain 
or loss, speech and visual difficulties, blurred or double vision, unusual smell 
and taste sensations, cognitive and/or behavioral changes, mood changes, and 
energy level changes (Rezai et al., 2008). 
 During titration sessions, PD patients are evaluated for the possible side 
effects of DBS and undergo a variety of other clinical assessments, including 
UPDRS-III, following a PD medication washout period. This ensures that the 
effects of DBS are readily observable and that clinician-initiated changes in 
stimulation parameters may be associated with changes in motor function. 
 Importantly, the stimulation parameters selected impact on the life of the 
internal pulse generator’s battery, which is typically removed and replaced 
intraoperatively every 2–5 years, although inductive-rechargeable batteries that 
last up to 9 years are available. When surgical lead placement is suboptimal or 
excessive lead migration occurs, higher levels of stimulation are required for 
adequate therapeutic effects, resulting in premature depletion of the implanted 
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battery. 
 
 
SUCCESSES 
 
 Patients undergoing DBS have obtained significant improvements in 
overall functioning, independence, quality of life enhancement, return to work or 
school and resumption of daily activities (Machado et al., 2006; Rezai et al., 2008; 
Malone et al., 2009). Two large clinical trials found STN neurostimulation to be 
superior in treating the motor complications of advanced Parkinson’s therapy 
compared to best medical management alone (Deuschl et al., 2006; Weaver et al., 
2009) 
 
 
LIMITATIONS 
 
Evidence from case studies and retrospective meta-analyses suggests that 
STN-DBS may lead to a variety of neuropsychological sequelae (e.g., mania, 
apathy, depression, suicidal ideation, impulsivity, attentional impairment, or 
memory deficits) (Voon et al., 2006; Parsons et al., 2006; Temel et al., 2006), but 
well-controlled studies report that the only consistent neuropsychological side 
effects of STN-DBS are impairments in verbal fluency and Stroop (i.e., an 
executive control task) performance (Voon et al., 2006; Obeso et al., 2011; 
Jahanshahi et al., 2000; Witt et al., 2004; Witt et al., 2006; Witt et al., 2013; 
Schroeder et al., 2002; Brittain et al., 2012). 
Standard therapeutic stimulation parameters of monopolar cathodic, 1–5 
V, 60–200 ms, and 120–180 Hz were determined primarily by trial and error 
(Rizzone et al., 2001; Moro et al., 2002; Volkmann et al., 2002; O’Suilleabhain et 
al., 2003) and postoperative titration remains an empirical exercise. This lack of 
understanding upsets the extension of DBS to patient populations that have few, 
if any, reliable treatment options. 
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PHYSIOLOGY 
 
The basal ganglia comprise subcortical nuclei with functions in distributed 
networks that modulate activity in motor, premotor, dorsolateral, anterior 
cingulate, and frontal eye field cortices (reviewed in Volkmann et al., 2010). 
The largest basal ganglia nucleus, the striatum, is associated with 
facilitated and suppressed states that are determined by the strength of cortical 
input, and is thought to act as a filter to increase signal-to-noise ratio (da Cunha 
et al., 2015). Striatal potentiation state is also determined by dopaminergic input 
from the substantia nigra pars compacta (SNpc), which can prevent transitions 
from suppressed to facilitated (da Cunha et al., 2015). In this way, the striatum 
integrates cortical and subcortical input (Bolam et al., 2000; Nambu et al., 2000; 
Miwa et al., 2001; Jaeger and Kita, 2011; Obeso et al., 2013; Surmeier, 2013; 
Ullsperger et al., 2014; Woolley et al., 2014), which is projected to the globus 
pallidus, whose internal segment serves as the major output structure of the 
basal ganglia. Basal ganglia output via the internal segment of the globus 
pallidus (GPi) gates thalamic activity, resulting in facilitation and suppression of 
cortical activity (reviewed in Wiecki & Frank, 2013). Thus, networks that include 
the basal ganglia play a role in the selection, facilitation, and inhibition of action, 
emotion, and cognition (reviewed in Volkmann et al., 2010). 
The STN is the only excitatory nucleus in the basal ganglia (Nambu et al., 
2002), and receives input from frontal areas involved in inhibition and executive 
control (reviewed in Jahanshahi, 2013) as well as subcortical input. Output to the 
GPi from the STN can suppress the gating of thalamic activity, resulting in 
decreased cortical activity (reviewed in Frank, 2006). 
 Importantly, the STN can be anatomically subdivided into functionally 
distinct regions (e.g., oculomotor, associative, limbic, and somatomotor) and 
cortico-subthalamic projections reflect this segregated, topographical 
organization (Afsharpour, 1985; Hartmann-von Monakow et al., 1978). However, 
the dendrites of STN neurons extend up to 1200 µm and so there may be 
considerable convergence of inputs from different cortical areas onto a single 
neuron in the STN (Yelnik & Percheron, 1979). 
In general, the dorsolateral subregion of the STN is relevant to 
somatomotor networks (Coyne et al., 2006), while the ventral subregion is 
relevant to associative and limbic processes (Alexander & Crutcher, 1990; Joel & 
Weiner, 1997; Karachi et al., 2005; Parent & Hazrati, 1995; Temel et al., 2005). This 
mirrors the segregation of motor and associative circuits found in other cortical 
and subcortical regions (Bevan et al., 2006; Romanelli et al., 2005), which enables 
parallel processing across multiple domains (Alexander & Crutcher, 1990). 
Neuronal oscillations reflect the synchronized activity of neuronal 
ensembles. Cortical gamma-band (~40–400 Hz) amplitude is increased (as the 
blood-oxygen level) during motor, visual, language, and cognitive tasks 
(Scheeringa et al., 2011) and is thought to reflect summed asynchronous spiking 
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activity (Manning et al., 2009). Abnormal inhibition of the cortical areas to which 
the BG project, including motor regions, is thought to explain the suppression of 
motor activity and impairment in motor sequencing observed in PD (Dubois et 
al., 1991; Willingham, 1998; de Hemptinne et al., 2013; Young & Penney, 1993). 
In PD, pathological beta-band (13–30 Hz) neuronal synchronization seems 
to occur in the basal ganglia (Hammond et al., 2007; Levy et al., 2000; Nini et al., 
1995) and specifically in the STN (Levy et al., 2002; Kuhn et al., 2005; Weinberger 
et al., 2006; Moran et al., 2008). Moreover, it appears that the pathological signal 
is locally generated in the STN (Kuhn et al., 2005, Levy et al., 2002) 
Suppression of this beta power in the STN using 2 standard treatments for 
PD, levodopa or DBS, is correlated with improvements in bradykinesia and 
rigidity (Kuhn et al., 2006; Weinberger et al., 2006; Kuhn et al., 2009; Ray et al., 
2008). Therapeutic effects of DBS of the STN in PD are also correlated with a 
reduction of beta-band activity in the motor circuitry (Kuhn et al., 2008). 
Reduction in tremor severity, on the other hand, is associated with 
decreases in low gamma (31–45 Hz) oscillations in the STN (Anzak et al., 2012). 
Both tremor amplitude and low gamma activity are suppressed by application of 
electrical stimulation, although reduction of tremor lags the reduction in gamma 
by several seconds and reemerges later than gamma increase after stimulation is 
discontinued (Beudel et al., 2015). Interestingly, low gamma activity in the STN is 
increased with cognitive load (Anzak et al., 2011; Anzak et al., 2013), which also 
increases resting tremor in PD patients (Deuschl et al., 1998). 
 Stimulation of limbic subregions of the STN may explain the experience of 
hypomanic and manic states following DBS (Mallet et al., 2007; Mandat et al., 
2006; Raucher-Chene et al., 2008). Studies have shown that stimulation in this 
region changes activation patterns in thalamic and cortical regions that are 
relevant to affect, while stimulation in more-dorsal regions of the STN result in 
motor network activation (Mallet et al., 2007). Additionally, there is evidence that 
DBS impairs the ability to recognize fearful content in faces and film sequences 
(Biseul et al., 2005; Vicente et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  21	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  22	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The current method of deep brain stimulation programming 
requires frequent clinical visits for adjustment of programming, 
which extends over a period of months. Stimulation titration is 
guided primarily by clinician impression, and the lack of objective 
methods for determining optimum parameters ensures that the 
process remains time-consuming. By providing the clinician with 
visualizations of patient-specific electrode location, models of tissue 
activation, and statistical data regarding efficacy at various 
stimulation locations, follow-up for DBS therapy could be simplified 
and even improved. In this study, we describe a computational 
pipeline for creation of such visualizations. 
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SUBJECTS 
 
 Subjects include patients with idiopathic PD undergoing unilateral STN-
DBS therapy (right: n = 15; left: n = 33) at the Center for Neuromodulation at The 
Ohio State University Wexner Medical Center (OSUWMC). All subjects provided 
informed consent for participation in the Atlas Protocol, in which demographic 
and clinical data was deidentified and stored in a secured database for 
subsequent study. In this retrospective analysis, the data collected includes 
preoperative neuroimaging, preoperative UPDRS-III assessments, postoperative 
neuroimaging, postoperative UPDRS-III assessments, stimulation parameters at 
follow-up visits for titration, and charted descriptions of adverse events. 
 Patients with significant comorbidities do not receive DBS treatment and 
are thus excluded from the database. Additional exclusion criteria for this study 
include the experience of significant adverse events including surgical or device 
complications (e.g., hemorrhage or severe infection requiring hospitalization or 
prolongation of existing hospitalization, lead fracture or other failures leading to 
surgical explantation or revision); significant cognitive impairment or dementia; 
uncontrolled depression, anxiety, or other mood disorder. Participants are also 
free to terminate their participation in the study at any time. 
 All implantations were performed at OSUWMC between 2010–2015, using 
Medtronic Neurological DBS leads (model 3389) and frame-based stereotactic 
technique with preoperative magnetic resonance neuroimaging. Post-
implantation, lead locations were verified with in-suite CT. Follow-up visits 
include UPDRS-III assessment in the unmedicated state with stimulation turned 
on. 
  
  
COMPUTATIONAL APPROACH 
 
An important goal of this study is to create a computational pipeline that 
utilizes clinical data (generally, outcome measures, neuroimaging, and 
neurostimulation parameters) to create statistical maps that will delineate the 
relationship between stimulated structures and clinical efficacy. 
To accomplish this, we normalize patient-specific neuroimaging data to 
the Montreal Neurological Institute 152 standard brain (Grabner et al., 2006) 
nonlinear/nonrigid tools available in the open-source neuroimaging software 
packages AFNI (Cox, 2011) and FSL (Smith et al., 2004). These measure overall 
image mismatch and provide a minimization algorithm that progressively 
optimizes a 4 ✕ 4 transformation matrix by first translating, rotating, scaling, and 
shearing the reference volume, and subsequently warping with nonlinear 
operations to align the volumes in fine morphological detail. 
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After modeling the subject anatomy in standard space, preoperative MRIs 
from each patient are coregistered with the postoperative CT using 
CRAnialVault Explorer (CRAVE) (D’Haese et al., 2012), which automatically 
extracts the x, y, z coordinates in subject space for the 4 electrode contacts on 
each DBS lead. We then apply the transformation matrix to the coordinates of the 
DBS leads to visualize in standard space. 
Using open-source analytical tools available in the Python programming 
language (van Rossum, 1995), we programmatically extract clinical outcome and 
titration data from the Atlas Database. In CRAVE, the stimulation parameters 
active during UPDRS-III assessments are masked into estimated volumes of 
tissue activation (VTAs), which are modeled at the appropriate electrode contact 
in subject space. We transform the VTA to standard space, as described above, 
and weight each voxel according to the reported change in UPDRS-III subscore, 
scaling by the number of subjects contributing to each voxel.  
By combining the neuroimaging and clinical data acquired from the large 
sample in the Atlas Database, we create statistical maps that can display trends 
in the relationship between subscore outcomes and stimulation location. 
To produce probabilistic maps that enable prediction of optimal 
stimulation locations, we extract x, y, z, and scaled outcome measures from each 
4 dimensional statistical map. We test these terms for predictive ability in a 
generalized linear model (GLM) with the following equation: 
 
scaled outcome  ~ x + y + z + x:y + y:z + x:z + x:y:z +  
x2 + y2 + z2 + x2:y2 + y2:z2 + x2:z2 + x2:y2:z2 +  
x3 + y3 + z3 + x3:y3 + y3:z3 + x3:z3 + x3:y3:z3 +  
x4 + y4 + z4 + x4:y4 + y4:z4 + x4:z4 + x4:y4:z4  
 
The GLM builds a manifold with its predictions, wherein each 1 mm3 
voxel contributes positively or negatively to an estimated change in outcome if it 
is included in the VTA at a given stimulation parameterization. 
We judge the success of the model by calculating Pearson's product-
moment correlation coefficient, first for all predictions made vs. actual outcomes 
for each subject independently to identify potential subject-level issues arising 
from pipeline processing failures. Then, we assess performance of the model in 
UPDRS-III subscore prediction across all of the data learned by each subscore 
manifold. 
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Figure 1. Sample VTA masks specified by stimulation parameters 
recorded at three visits. A: [0+/1-/2-] 3.0 V, 120 µs, 150 Hz. B: [0+/2-] 
2.0 V, 60 µs, 150 Hz. C: [2+/1-] 3.6 V, 130 µs, 185 Hz. 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  27	  
 
 
 
 
 
 
Figure 2. Pre-
operative MRI for 
subject 120 
captures 
anatomical detail.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Montreal 
Neurological 
Institute standard 
brain created using 
152 subjects.  
 
 
 
 
 
 
 
 
 
Figure 6. MRI of 
subject 120, 
normalized to 
standard brain to 
allow between-
subject 
comparisons of 
anatomical data.  	  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Post-
operative CT for 
subject 120 reveals 
location of DBS 
leads (white 
arrow).  
 
 
 
 
 
 
 
 
 
 
Figure 5. Co-
registration of CT 
to MRI. DBS lead 
location can thus be 
determined 
accurately in MRI 
space.  
 
 	  
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  28	  
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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The results of the subject-level examination of probabilistic manifold 
accuracy are shown in Table 1. In this iteration of the pipeline, the highest 
correlations between actual and predicted outcomes are seen for subject 66 (r = 
0.997), who is undergoing right hemisphere STN-DBS, and subject 191 (r = 0.997), 
who is receiving stimulation in the left STN. Predictions made for these 
individuals derive from the model's instruction on fewer than 20 observations 
(for subject 66, n = 17; for subject 191, n = 18). In the case of these two subjects, 
model predictions underestimate the outcome: predictions for subject 66 are 85% 
less than actual outcome, while predictions for subject 191 are 66% less than 
actual outcome. 
Predictions made concerning UPDRS-III outcomes for subject 129, who is 
implanted at the left STN, are least correlated with the actual outcomes (r = 0.063, 
n = 11), with similar model divergence observed for subject 65 (left-implanted, r 
= 0.162), who contributed 63 observations to the instruction of the model. 
Although probabilistic manifolds for 40 out of 48 subjects correlate positively 
with actual outcomes at r > 0.600, predictions for subject 1 (right STN-DBS 
patient) and subject 48 (left STN-DBS patient) are negatively correlated with 
actual outcomes (respectively, r = -0.575, n = 14 and r = -0.135, n = 10). 
Table 2 displays the performance of the model on the subscore-level for 
observations involving right-implanted subjects. Predictions for tremor at rest of 
the face, arising from chair, facial expression, and speech are the most highly 
correlated to actual outcomes (respectively, r = 0.901, n = 8; r = 0.769, n = 10; r = 
0.577, n = 21; r = 0.539, n = 14). For total UPDRS-III score predictions, there is not 
a strong linear correlation to actual outcomes (r = 0.110, n = 39) and the average 
percent error between actual and predicted outcome is 93%. 
Table 3 displays the same information for predictions involving the left 
side. The strongest linear relationships observed come from predictions 
concerning ipsilateral motor outcome (left hand movements, r = 0.607, n = 61; 
left-handed finger taps, r = 0.533, n = 65; left upper extremity posture, r = 0.491, n 
= 63; left-handed rapid alternating movements, r = 0.436, n = 51). Predictions of 
total UPDRS-III outcome do not strongly correlate to actual outcome (r = 0.249, n 
=115) and are 70% less than actual outcome. 
Statistical maps for selected subscores are shown in Figures 7-18, along 
with visualizations of subscore-specific probabilistic manifolds. In the top panel 
of Figure 7, the statistical map of left upper extremity tremor outcome 
demonstrates that stimulation applied to the dorsomedial, dorsolateral, and 
anterior regions of the right STN corresponds to a decline in the outcome 
measure, while ventral stimulation corresponds to improvement. In the bottom 
panel, it is clear that the manifold captures both the detrimental effects of 
dorsomedial, dorsolateral, and anterior stimulation, as well as the adjuvant 
effects of ventral stimulation. 
In Figure 8, the statistical map suggests benefits of left STN-DBS on right 
upper extremity tremor outcome regardless of stimulation location, although 
dorsal stimulation is associated with the greatest improvement. However, it is 
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noteworthy that the probabilistic manifold reveals a region in the posterior, 
inferior aspect of the left STN which may predispose to decline when the 
therapeutic VTA falls within its boundaries. 
Figures 9 and 10 show statistical maps and probabilistic manifolds for leg 
agility outcomes in right-side and left-side subjects, respectively. The outcome 
for right STN stimulation is negatively impacted by dorsally and anteriorly-
directed stimulation, and the manifold learns a relatively well-defined region of 
space to be avoided. Interestingly, the outcome for left STN stimulation tends to 
decline with dorsal stimulation as well as posterior, ventral stimulation, and the 
probabilistic manifold successfully captures the necessity of avoiding each 
distinct regions. 
As can be seen in Figures 11 and 12, body bradykinesia and hypokinesia 
outcome is generally improved following stimulation anywhere within or 
around the STN, with little difference between right and left implantations. The 
right and left-sided statistical maps for this outcome suggest a detriment 
following ventral stimulation, although this effect is not strong enough to appear 
in the predictions of the probabilistic manifold of either the right or left side. 
The statistical map and probabilistic manifold for gait outcome following 
right STN-DBS is shown in Figure 13. Stimulation in most regions leads to 
improvement, especially when directed ventrally, although a limited location 
dorsal to the STN is associated with decline. For the left STN (Figure 14), ventral 
regions within the STN and locations dorsal to it actually correspond to 
improvement, and the manifold predicts decline will occur when stimulation 
reaches areas that correspond to improvement for the right STN. 
From Figure 15, we see that stimulation at the dorsal tip of the STN, as 
well as at dorsal regions outside of the STN, leads to decline in speech 
performance. However, for the left STN (Figure 16), declines in speech outcome 
occurs when stimulation is applied to ventromedial areas. 
 Figures 17 and 18 display statistical maps and probabilistic manifolds for 
the UPDRS-III composite of all subscores, less those for muscles ipsilateral to the 
implanted STN. For right-side implantations, most areas correspond with 
improvement, although decline is likely with lateral and dorsomedial 
stimulation. On the left side, all regions but the posterior lateral region outside of 
the STN leads to improvement. 
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Table 1. Summary comparison of actual outcomes vs. model predictions for 
every subscore in UPDRS-III for each of 48 subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
implanted side subject observations Pearson's r avg. percent error
right 1 14 -0.575 46
right 7 15 0.891 35
right 16 37 0.981 -48
right 28 135 0.835 -69
right 42 49 0.937 -67
right 52 29 0.739 -140
right 66 17 0.997 -85
right 73 37 0.984 -27
right 83 18 0.980 -54
right 84 33 0.685 -41
right 87 50 0.938 -70
right 99 81 0.832 8
right 144 11 0.977 -53
right 146 17 0.992 -37
right 210 26 0.902 -52
left 4 138 0.916 -79
left 11 17 0.594 5
left 15 146 0.917 -38
left 26 99 0.902 -67
left 32 34 0.993 -78
left 41 45 0.887 -72
left 43 70 0.778 -42
left 45 16 0.531 -51
left 47 37 0.850 -39
left 48 10 -0.135 31
left 50 102 0.821 -74
left 54 80 0.956 -64
left 56 71 0.752 -34
left 57 67 0.936 -73
left 61 81 0.879 -76
left 63 36 0.983 -84
left 65 63 0.162 -9
left 67 104 0.834 -69
left 69 70 0.824 -63
left 72 90 0.857 -83
left 75 35 0.974 -78
left 82 53 0.886 -72
left 90 61 0.635 -33
left 105 25 0.498 -3
left 106 69 0.972 -42
left 117 35 0.329 -38
left 120 12 0.986 -87
left 129 11 0.063 4
left 132 65 0.795 -9
left 139 39 0.958 -69
left 156 44 0.829 -36
left 167 19 0.994 -80
left 191 18 0.997 -66
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Table 2. Summary comparison of actual outcomes vs. model predictions for each 
subscore in UPDRS-III for right-implanted subjects. Ipsilateral motor outcome 
statistics are shown in faded text. (U.E.: upper extremity; L.E.: lower extremity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UPDRS subscore implanted side observations Pearson's r avg. percent error
tremor at rest (face) right 8 0.901 -40
rigidity (neck) right 23 0.224 -41
speech right 14 0.539 -30
facial expression right 21 0.577 -44
body bradykinesia and hypokinesia right 32 -0.102 -54
posture right 23 0.485 -15
postural stability right 18 0.238 36
gait right 27 0.361 -31
arising from chair right 10 0.769 0
tremor at rest (right U.E.) right 21 0.239 -51
rigidity (right U.E.) right 29 0.218 -41
rapid alternating (right U.E.) right 24 0.162 -23
action postural (right U.E.) right 15 0.381 -13
hand movements (right U.E.) right 17 -0.036 -44
finger taps (right U.E.) right 24 0.004 -41
tremor at rest (right L.E.) right 18 -0.140 -29
rigidity (right L.E.) right 28 -0.269 -57
leg agility (right L.E.) right 22 0.503 3
tremor at rest (left U.E.) right 22 0.334 -37
rigidity (left U.E.) right 32 0.191 -57
rapid alternating (left U.E.) right 28 0.333 -60
action postural (left U.E.) right 19 0.295 -41
hand movements (left U.E.) right 31 -0.335 -65
finger taps (left U.E.) right 35 -0.043 -62
tremor at rest (left L.E.) right 18 0.493 -36
rigidity (left L.E.) right 30 -0.189 -58
leg agility (left L.E.) right 22 0.312 -7
UPDRS-III total right 39 0.110 -93
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Table 3. Summary comparison of actual outcomes vs. model predictions for each 
subscore in UPDRS-III for right-implanted subjects. Ipsilateral motor outcome 
statistics are shown in faded text. (U.E.: upper extremity; L.E.: lower extremity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UPDRS subscore implanted side observations Pearson's r avg. percent error
tremor at rest (face) left 44 0.361 -34
rigidity (neck) left 78 -0.048 -44
speech left 52 0.307 -33
facial expression left 69 0.207 -48
body bradykinesia and hypokinesia left 97 0.065 -63
posture left 58 0.381 -18
postural stability left 64 0.100 -33
gait left 57 0.192 -31
arising from chair left 50 0.345 -40
tremor at rest (right U.E.) left 95 0.092 -57
rigidity (right U.E.) left 110 0.148 -62
rapid alternating (right U.E.) left 83 0.107 -57
action postural (right U.E.) left 104 0.050 -66
hand movements (right U.E.) left 85 0.150 -60
finger taps (right U.E.) left 97 0.066 -60
tremor at rest (right L.E.) left 88 0.254 -62
rigidity (right L.E.) left 90 0.258 -57
leg agility (right L.E.) left 79 0.377 -49
tremor at rest (left U.E.) left 57 0.323 -6
rigidity (left U.E.) left 65 0.221 -15
rapid alternating (left U.E.) left 51 0.436 -21
action postural (left U.E.) left 63 0.491 -22
hand movements (left U.E.) left 61 0.607 -37
finger taps (left U.E.) left 65 0.533 -36
tremor at rest (left L.E.) left 45 0.125 -21
rigidity (left L.E.) left 72 0.379 -41
leg agility (left L.E.) left 63 0.404 4
UPDRS-III total left 115 0.249 -70
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Figure 7. Top panel: Statistical map of left upper extremity tremor outcome for 
right-implanted subjects (radiological orientation). Bottom panel: Probabilistic 
manifold of left upper extremity tremor outcome for right-implanted subjects 
(radiological orientation). 
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Figure 8. Top panel: Statistical map of right upper extremity tremor outcome for 
left-implanted subjects (radiological orientation). Bottom panel: Probabilistic 
manifold of right upper extremity tremor outcome for left-implanted subjects 
(radiological orientation). 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  36	  
 
 
 
         2             0    -2 
 
   0.002            0            -0.002 
 
 
Figure 9. Top panel: Statistical map of left-leg agility outcome for right-implanted 
subjects (radiological orientation). Bottom panel: Probabilistic manifold of left-leg 
agility outcome for right-implanted subjects (radiological orientation). 
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Figure 10. Top panel: Statistical map of right-leg agility outcome for left-
implanted subjects (radiological orientation). Bottom panel: Probabilistic 
manifold of right-leg agility outcome for left-implanted subjects (radiological 
orientation). 
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Figure 11. Top panel: Statistical map of body bradykinesia and hypokinesia 
outcome for right-implanted subjects (radiological orientation). Bottom panel: 
Probabilistic manifold of body bradykinesia and hypokinesia outcome for right-
implanted subjects (radiological orientation). 
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Figure 12. Top panel: Statistical map of body bradykinesia and hypokinesia 
outcome for left-implanted subjects (radiological orientation). Bottom panel: 
Probabilistic manifold of body bradykinesia and hypokinesia outcome for left-
implanted subjects (radiological orientation). 
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Figure 13. Top panel: Statistical map of gait outcome for right-implanted subjects 
(radiological orientation). Bottom panel: Probabilistic manifold of gait outcome 
for right-implanted subjects (radiological orientation). 
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Figure 14. Top panel: Statistical map of gait outcome for left-implanted subjects  
(radiological orientation). Bottom panel: Probabilistic manifold of gait outcome 
for left-implanted subjects (radiological orientation). 
 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  42	  
 
 
 
         1             0    -1 
 
   0.001            0            -0.001 
 
 
Figure 15. Top panel: Statistical map of speech outcome for right-implanted 
subjects (radiological orientation). Bottom panel: Probabilistic manifold of speech 
outcome for right-implanted subjects (radiological orientation). 
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Figure 16. Top panel: Statistical map of speech outcome for left-implanted 
subjects (radiological orientation). Bottom panel: Probabilistic manifold of speech 
outcome for left-implanted subjects (radiological orientation). 
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Figure 17. Top panel: Statistical map of left-side UPDRS-III outcome for right-
implanted subjects (radiological orientation). Bottom panel: Probabilistic 
manifold of left-side UPDRS-III outcome for right-implanted subjects 
(radiological orientation). 
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Figure 18. Top panel: Statistical map of right-side UPDRS-III outcome for left-
implanted subjects (radiological orientation). Bottom panel: Probabilistic 
manifold of right-side UPDRS-III outcome for left-implanted subjects 
(radiological orientation). 
 
 
 
 
 
Peter	  Joshua	  Hamer	   	   Undergraduate	  Research	  Thesis	  
July,	  2015	  46	  
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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The statistical analysis of the model's predictive ability qualitatively 
demonstrates its success for most subjects and most subscores. Failures at 
the subject level may be attributed to varying levels of success of the 
neuroimaging processing steps of the pipeline, which is currently left 
unquantified. Future iterations of the pipeline, therefore, should include model 
terms for the accuracy of standardization steps taken for each subject. Subscore-
level failures, on the other hand, may reflect the fact that not all aspects of motor 
dysfunction in PD are amenable to treatment with DBS, or that some particular 
outcome is not predominantly determined by stimulation at specific locations in 
and around the STN. 
Previous studies suggest that stimulation anywhere in the vicinity of the 
STN may lead to motor improvement as assessed by UPDRS-III (Kasasbeh et al., 
2013; Eisenstein et al., 2014). By and large, this finding is replicated here and can 
be explained by the fact that there is anatomical overlap between functionally 
segregated subregions of the STN (Alkemade et al., 2015). 
It is crucial to note, however, that this analysis is the first that we know of 
to examine each subscore of UPDRS-III for the effects of location-specific 
stimulation, and as such, validation of the model's predictions is incomplete. In 
this respect, prospective comparison of actual and predicted outcomes, ideally 
from subjects whose previous data do not inform the creation of the model, 
would provide a useful evaluation. 
The estimation of VTAs in the pipeline is rudimentary, but highly 
amenable to computation. In future studies with more advanced computational 
tools, we could model tissue activation separately for cell bodies and fiber tracts, 
which will provide exceptionally greater accuracy in determining the spread of 
electrical stimulation. 
Further development of the pipeline described must include a cross-
validation step, wherein each term of the GLM is evaluated for predictive utility. 
Given that each term in the presented model relates solely to anatomical location, 
it is essential to include other terms in the cross-validation, such as subject age, 
length of time since surgery, and the success of neuroimaging processing. 
Upon validation of the probabilistic manifolds for individual UPDRS-
III subscores, multiple subscores may be modeled simultaneously to create a tool 
that is useful to the clinician caring for a PD patient whose chief complaints 
revolve around multiple symptoms. If such an approach is supported through 
further validation studies, it may improve the ability to personalize DBS therapy 
to the symptoms of a particular patient. 
Finally, recent advances in neuroimaging, DBS electrode design, and 
functional neurosurgical techniques will allow for ever more minute control of 
therapeutic stimulation. To help such progress translate to the increased efficacy 
of STN-DBS in PD, approaches such as that described will be required. 
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